Inspire's reimbursement fix and raised guidance drive the story
New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.
This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.
Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.
The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.
Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.
This explains the operational response to the reimbursement disruption and how the company plans to restore growth.
Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.
These are secondary but supportive signals of governance and relative performance that round out the picture.